Madrid, Spain-headquartered PharmaMar (MCE: PHM) has presented positive results at the American Society of Hematology (ASH) annual meeting in Atlanta, Georgia.
The presentation of data from the Phase III ADMYRE study showed that a combination of plitidepsin and dexamethasone achieved superior progression-free survival (PFS) versus dexamethasone alone.
The study, which is evaluating PharmaMar's hematology candidate in patients with relapsed or relapsed and refractory multiple myeloma, revealed a 3.8 month PFS compared with 1.9 months on dexamethasone alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze